Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/185963
Title: | Healthcare delivery for HIV-positive people with tuberculosis in Europe |
Author: | Bentzon, Adrian Panteleev, Alexander Mitsura, V. Borodulina, Elena Skrahin, Aliaksandr Denisova, Elena Tetradov, Simona Podlasin, Regina Riekstina, V. Kancauskiene, Z. Paduto, D. Mocroft, Amanda Trofimova, T. Miller, Robert F. Post, F. Grzeszczuk, Anna Lundgren, Jens D. Inglot, M. Podlekareva, Daria N. Bolokadze, N. Kirk, Ole TB:HIV Study Group. Miró Meda, José M. |
Keywords: | Tuberculosi VIH (Virus) Epidemiologia Europa Tuberculosis HIV (Viruses) Epidemiology Europe |
Issue Date: | 20-Oct-2020 |
Publisher: | Wiley |
Abstract: | Background: In a 2013 survey, we reported distinct discrepancies in delivery of tuberculosis (TB) and HIV services in eastern Europe (EE) vs. western Europe (WE). Objectives: To verify the differences in TB and HIV services in EE vs. WE. Methods: Twenty-three sites completed a survey in 2018 (EE, 14; WE, nine; 88% response rate). Results were compared across as well as within the two regions. When possible, results were compared with the 2013 survey. Results: Delivery of healthcare was significantly less integrated in EE: provision of TB and HIV services at one site (36% in EE vs. 89% in WE; P = 0.034), and continued TB follow-up in one location (42% vs. 100%; P = 0.007). Although access to TB diagnostics, standard TB and HIV drugs was generally good, fewer sites in EE reported unlimited access to rifabutin/multi-drug-resistant TB (MDR-TB) drugs, HIV integrase inhibitors and opioid substitution therapy (OST). Compared with 2013, routine usage of GeneXpert was more common in EE in 2018 (54% vs. 92%; P = 0.073), as was access to moxifloxacin (46% vs. 91%; P = 0.033), linezolid (31% vs. 64%; P = 0.217), and bedaquiline (0% vs. 25%; P = 0.217). Integration of TB and HIV services (46% vs. 39%; P = 1.000) and provision of OST to patients with opioid dependency (54% vs. 46%; P = 0.695) remained unchanged. Conclusion: Delivery of TB and HIV healthcare, including integration of TB and HIV care and access to MDR-TB drugs, still differs between WE and EE, as well as between individual EE sites. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1111/hiv.13016 |
It is part of: | HIV Medicine, 2020, vol. 22, num. 4, p. 283-293 |
URI: | http://hdl.handle.net/2445/185963 |
Related resource: | https://doi.org/10.1111/hiv.13016 |
ISSN: | 1464-2662 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
708099.pdf | 518.11 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.